NASDAQ:BLCM Bellicum Pharmaceuticals Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Bellicum Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $1.21 -0.01 (-0.82%) (As of 06/24/2022 04:00 PM ET) Add Compare Share Today's Range$1.20▼$1.2550-Day Range$1.02▼$2.0052-Week Range$1.00▼$4.04Volume7,956 shsAverage Volume42,355 shsMarket Capitalization$10.42 millionP/E RatioN/ADividend YieldN/APrice Target$5.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive BLCM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bellicum Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address BLCM Stock Forecast (MarketRank)Overall MarketRank™1.86 out of 5 starsMedical Sector730th out of 1,418 stocksPharmaceutical Preparations Industry354th out of 679 stocksAnalyst Opinion: 3.5Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 - 3.5 Analyst's Opinion Consensus RatingBellicum Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.00, Bellicum Pharmaceuticals has a forecasted upside of 313.2% from its current price of $1.21.Amount of Analyst CoverageBellicum Pharmaceuticals has received no research coverage in the past 90 days. Previous Next 4.5 Community Rank Outperform VotesBellicum Pharmaceuticals has received 358 “outperform” votes. (Add your “outperform” vote.)Underperform VotesBellicum Pharmaceuticals has received 172 “underperform” votes. (Add your “underperform” vote.)Community SentimentBellicum Pharmaceuticals has received 67.55% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Bellicum Pharmaceuticals and other stocks. Vote “Outperform” if you believe BLCM will outperform the S&P 500 over the long term. Vote “Underperform” if you believe BLCM will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldBellicum Pharmaceuticals does not currently pay a dividend.Dividend GrowthBellicum Pharmaceuticals does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Bellicum Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.72% of the stock of Bellicum Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 28.09% of the stock of Bellicum Pharmaceuticals is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Bellicum Pharmaceuticals are expected to grow in the coming year, from ($1.82) to ($1.48) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Bellicum Pharmaceuticals is -4.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Bellicum Pharmaceuticals is -4.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBellicum Pharmaceuticals has a P/B Ratio of 0.42. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Bellicum Pharmaceuticals (NASDAQ:BLCM)Bellicum Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen; and BPX-603, a dual-switch GoCAR-T product candidate that is in Phase 1/2 clinical trials to treat solid tumors that express the human epidermal growth factor receptor 2 antigens. Its clinical product candidates also include Rivo-cel, an allogeneic T cell product candidate intended to enhance outcomes in the treatment of leukemias, lymphomas, and inherited blood disorders. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc.; BioVec Pharma, Inc.; ARIAD Pharmaceuticals, Inc.; and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in Houston, Texas.Read More BLCM Stock News HeadlinesJune 23, 2022 | americanbankingnews.comBellicum Pharmaceuticals (NASDAQ:BLCM) Now Covered by Analysts at StockNews.comJune 16, 2022 | americanbankingnews.comStockNews.com Initiates Coverage on Bellicum Pharmaceuticals (NASDAQ:BLCM)June 11, 2022 | americanbankingnews.comBellicum Pharmaceuticals (NASDAQ:BLCM) & Revance Therapeutics (NASDAQ:RVNC) Head to Head ReviewJune 6, 2022 | americanbankingnews.comStockNews.com Begins Coverage on Bellicum Pharmaceuticals (NASDAQ:BLCM)May 31, 2022 | americanbankingnews.comBellicum Pharmaceuticals (NASDAQ:BLCM) Upgraded by Zacks Investment Research to HoldMay 13, 2022 | seekingalpha.comBellicum Pharmaceuticals GAAP EPS of -$0.25 beats by $0.42May 13, 2022 | finance.yahoo.comBellicum Reports First Quarter 2022 Financial Results and Provides Operational UpdateMarch 24, 2022 | finance.yahoo.comBellicum Reports Fourth Quarter 2021 Financial Results and Provides Operational UpdateFebruary 16, 2022 | benzinga.comLadenburg Thalmann Initiates Coverage On Bellicum Pharmaceuticals with Buy Rating, Announces Price Target of $5January 26, 2022 | finance.yahoo.comBellicum Pharmaceuticals to Participate in the B. Riley Securities 2022 Virtual Oncology ConferenceDecember 13, 2021 | finance.yahoo.comBellicum Regains Compliance with Nasdaq Continued Listing RequirementsDecember 10, 2021 | finance.yahoo.comSumitovant Biopharma Highlights Significant Clinical, Regulatory and Commercial Achievements Across its Portfolio of Companies in the Second Quarter of FY2021December 7, 2021 | msn.comBellicum Secures $35M Via Equity Funding, Posts Interim Data From Early GoCAR-T Cancer StudiesSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BLCM CUSIPN/A CIK1358403 Webwww.bellicum.com Phone(832) 384-1100FaxN/AEmployees7Year FoundedN/ACompany Calendar Last Earnings5/12/2022Today6/24/2022Next Earnings (Estimated)8/11/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$5.00 High Stock Price Forecast$5.00 Low Stock Price Forecast$5.00 Forecasted Upside/Downside+313.2%Consensus RatingBuy Rating Score (0-4)3 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.29) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-9.70 million Net MarginsN/A Pretax Margin-96.77% Return on Equity-324.01% Return on Assets-35.96% Debt Debt-to-Equity RatioN/A Current Ratio5.45 Quick Ratio5.45 Sales & Book Value Annual Sales$6.20 million Price / Sales1.68 Cash FlowN/A Price / Cash FlowN/A Book Value$2.90 per share Price / Book0.42Miscellaneous Outstanding Shares8,610,000Free Float8,376,000Market Cap$10.42 million OptionableOptionable Beta1.46 Bellicum Pharmaceuticals Frequently Asked Questions Should I buy or sell Bellicum Pharmaceuticals stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bellicum Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Bellicum Pharmaceuticals stock. View analyst ratings for Bellicum Pharmaceuticals or view top-rated stocks. What is Bellicum Pharmaceuticals' stock price forecast for 2022? 1 Wall Street analysts have issued 12-month price objectives for Bellicum Pharmaceuticals' shares. Their BLCM stock forecasts range from $5.00 to $5.00. On average, they predict Bellicum Pharmaceuticals' stock price to reach $5.00 in the next year. This suggests a possible upside of 313.2% from the stock's current price. View analysts' price targets for Bellicum Pharmaceuticals or view top-rated stocks among Wall Street analysts. How has Bellicum Pharmaceuticals' stock performed in 2022? Bellicum Pharmaceuticals' stock was trading at $1.49 on January 1st, 2022. Since then, BLCM shares have decreased by 18.8% and is now trading at $1.21. View the best growth stocks for 2022 here. When is Bellicum Pharmaceuticals' next earnings date? Bellicum Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022. View our earnings forecast for Bellicum Pharmaceuticals. How were Bellicum Pharmaceuticals' earnings last quarter? Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) released its quarterly earnings data on Thursday, May, 12th. The biopharmaceutical company reported ($0.25) earnings per share for the quarter. View Bellicum Pharmaceuticals' earnings history. When did Bellicum Pharmaceuticals' stock split? How did Bellicum Pharmaceuticals' stock split work? Bellicum Pharmaceuticals's stock reverse split before market open on Thursday, February 6th 2020. The 1-10 reverse split was announced on Wednesday, February 5th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, February 5th 2020. An investor that had 100 shares of Bellicum Pharmaceuticals stock prior to the reverse split would have 10 shares after the split. Who are Bellicum Pharmaceuticals' key executives? Bellicum Pharmaceuticals' management team includes the following people: Mr. Richard A. Fair, Pres, CEO & Director (Age 53, Pay $915.28k)Ms. Charity D. Scripture M.S., Pharm.D., Chief Devel. Officer (Age 47, Pay $226.23k)Mr. Charles S. Grass, Principal Accounting Officer (Age 62)Mr. Joseph Senesac, Sr. VP of Technical Operations & Quality (Age 52)Dr. Alan K. Smith Ph.D., Chief Scientific Officer (Age 64)Dr. Aaron E. Foster, Head of Research & Sr. VP (Age 49) Who are some of Bellicum Pharmaceuticals' key competitors? Some companies that are related to Bellicum Pharmaceuticals include NuCana (NCNA), NRx Pharmaceuticals (NRXP), Ampio Pharmaceuticals (AMPE), Ampio Pharmaceuticals (AMPE), Corvus Pharmaceuticals (CRVS), Acasti Pharma (ACST), Longboard Pharmaceuticals (LBPH), Biofrontera (BFRI), Astria Therapeutics (ATXS), Societal CDMO (SCTL), Spruce Biosciences (SPRB), Galera Therapeutics (GRTX), Acurx Pharmaceuticals (ACXP), Oragenics (OGEN) and Oragenics (OGEN). View all of BLCM's competitors. What other stocks do shareholders of Bellicum Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Bellicum Pharmaceuticals investors own include Arrowhead Pharmaceuticals (ARWR), Alliance Resource Partners (ARLP), AVEO Pharmaceuticals (AVEO), TransEnterix (TRXC), CyberArk Software (CYBR), AcelRx Pharmaceuticals (ACRX), Gilead Sciences (GILD), Novavax (NVAX), Pfizer (PFE) and Inovio Pharmaceuticals (INO). When did Bellicum Pharmaceuticals IPO? (BLCM) raised $101 million in an IPO on Thursday, December 18th 2014. The company issued 6,300,000 shares at $15.00-$17.00 per share. Jefferies, Citigroup and Piper Jaffray served as the underwriters for the IPO and Trout Capital was co-manager. What is Bellicum Pharmaceuticals' stock symbol? Bellicum Pharmaceuticals trades on the NASDAQ under the ticker symbol "BLCM." Who are Bellicum Pharmaceuticals' major shareholders? Bellicum Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (4.24%) and Concourse Financial Group Securities Inc. (0.00%). Company insiders that own Bellicum Pharmaceuticals stock include Richard A Fair and Shane Ward. View institutional ownership trends for Bellicum Pharmaceuticals. Which major investors are selling Bellicum Pharmaceuticals stock? BLCM stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc.. View insider buying and selling activity for Bellicum Pharmaceuticals or view top insider-selling stocks. How do I buy shares of Bellicum Pharmaceuticals? Shares of BLCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Bellicum Pharmaceuticals' stock price today? One share of BLCM stock can currently be purchased for approximately $1.21. How much money does Bellicum Pharmaceuticals make? Bellicum Pharmaceuticals (NASDAQ:BLCM) has a market capitalization of $10.42 million and generates $6.20 million in revenue each year. The biopharmaceutical company earns $-9.70 million in net income (profit) each year or ($0.29) on an earnings per share basis. How many employees does Bellicum Pharmaceuticals have? Bellicum Pharmaceuticals employs 7 workers across the globe. How can I contact Bellicum Pharmaceuticals? Bellicum Pharmaceuticals' mailing address is 2130 WEST HOLCOMBE BOULEVARD SUITE 800, HOUSTON TX, 77030. The official website for Bellicum Pharmaceuticals is www.bellicum.com. The biopharmaceutical company can be reached via phone at (832) 384-1100 or via email at [email protected]. This page (NASDAQ:BLCM) was last updated on 6/24/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
